Identification and validation of hits from high throughput screens for CFTR modulators

Current Pharmaceutical Design

Volumn 18, Issue 5, 2012, Pages 628-641

  Pasyk, Stan ^a   Molinski, Steven ^a   Yu, Wilson ^a   Eckford, Paul D W ^a   Bear, Christine E ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Biological validation; High throughput screening; In silico screening; Selection of appropriate animal and cellular models

Indexed keywords

IVACAFTOR; LUMACAFTOR; NATURAL PRODUCT; PLACEBO; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VX 661;

ARTICLE; BIOLOGICAL ACTIVITY; CELL CULTURE; CLINICAL TRIAL; CYSTIC FIBROSIS; CYTOLOGY; DRUG SCREENING; ELECTROPHYSIOLOGY; EPITHELIUM CELL; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC IDENTIFICATION; HUMAN; MEMBRANE POTENTIAL; MOLECULAR DOCKING; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN BINDING; STEM CELL;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DESIGN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; SMALL MOLECULE LIBRARIES;

EID: 84856463093     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799315957     Document Type: Article

References (87)

1. Proesmans M, Vermeulen F, De Boeck K. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur J Pediatr 2008; 167: 839-49.
2. Messick J. A 21st-century approach to cystic fibrosis: optimizing outcomes across the disease spectrum. J Pediatr Gastroenterol Nutr 2010; 51 Suppl 7: S1-7; quiz 3 p following S7.
3. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009; 54: 595-605.
4. Grasemann H, Ratjen F. Emerging therapies for cystic fibrosis lung disease. Expert Opin Emerg Drugs 2010; 15: 653-9.
5. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006; 440: 477-83.
6. Mornon JP, Lehn P, Callebaut I. Atomic model of human cystic fibrosis transmembrane conductance regulator: membranespanning domains and coupling interfaces. Cell Mol Life Sci 2008; 65: 2594-612.
7. Mornon JP, Lehn P, Callebaut I. Molecular models of the open and closed states of the whole human CFTR protein. Cell Mol Life Sci 2009; 66: 3469-86.
8. Serohijos AW, Hegedus T, Aleksandrov AA, et al. Phenylalanine- 508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci USA 2008; 105: 3256-61.
9. Amaral MD. Processing of CFTR: traversing the cellular maze-- how much CFTR needs to go through to avoid cystic fibrosis? Pediatr Pulmonol 2005; 39: 479-91.
10. Denning GM, Anderson MP, Amara JF, et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761-4.
11. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996; 1: 117-25.
12. Okiyoneda T, Barriere H, Bagdany M, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science; 329: 805-10.
13. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106: 18825-30.
14. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med; 363: 1991-2003.
15. Zhou JZ. Chemoinformatics and library design. Methods Mol Biol; 685: 27-52.
16. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1117-30.
17. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-71.
18. Carlile GW, Robert R, Zhang D, et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem 2007; 8: 1012-20.
19. Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008; 73: 478-89.
20. Tradtrantip L, Yangthara B, Padmawar P, Morrison C, Verkman AS. Thiophenecarboxylate suppressor of cyclic nucleotides discovered in a small-molecule screen blocks toxin-induced intestinal fluid secretion. Mol Pharmacol 2009; 75: 134-42.
21. Kalid O, Mense M, Fischman S, et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des; 24: 971-91.
22. Lin S, Sui J, Cotard S, et al. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Assay Drug Dev Technol; 8: 669-84.
23. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
24. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60: 55-9.
25. Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 506-15.
26. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-77.
27. Rommens JM, Dho S, Bear CE, et al. CAMP-inducible chloride conductance in mouse fibroblast lines stably expressing the human cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 1991; 88: 7500-4.
28. Illek B, Fischer H, Santos GF, et al. CAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am J Physiol 1995; 268: C886-93.
29. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304: 600-2.
30. Villoutreix BO, Eudes R, Miteva MA. Structure-based virtual ligand screening: recent success stories. Comb Chem High Throughput Screen 2009; 12: 1000-16.
31. Ebalunode JO, Zheng W, Tropsha A. Application of QSAR and shape pharmacophore modeling approaches for targeted chemical library design. Methods Mol Biol; 685: 111-33.
32. Gao Q, Yang L, Zhu Y. Pharmacophore based drug design approach as a practical process in drug discovery. Curr Comput Aided Drug Des; 6: 37-49.
33. Warner DJ, Vadolia MM, Laughton CA, Kerr ID, Doughty SW. Modelling the restoration of wild-type dynamic behaviour in DeltaF508- CFTR NBD1 by 8-cyclopentyl-1,3-dipropylxanthine. J Mol Graph Model 2007; 26: 691-9.
34. Klebe G, Kramer O, Sotriffer C. Strategies for the design of inhibitors of aldose reductase, an enzyme showing pronounced inducedfit adaptations. Cell Mol Life Sci 2004; 61: 783-93.
35. Evers A, Klabunde T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem 2005; 48: 1088-97.
36. Varady J, Wu X, Fang X, et al. Molecular modeling of the threedimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J Med Chem 2003; 46: 4377-92.
37. Dawson RJ, Locher KP. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett 2007; 581: 935-8.
38. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006; 443: 180-5.
39. DeGorter MK, Conseil G, Deeley RG, Campbell RL, Cole SP. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochem Biophys Res Commun 2008; 365: 29-34.
40. El-Sheikh AA, van den Heuvel JJ, Krieger E, Russel FG, Koenderink JB. Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol Pharmacol 2008; 74: 964-71.
41. Ravna AW, Sylte I, Sager G. Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5). Theor Biol Med Model 2007; 4: 33.
42. Zolnerciks JK, Wooding C, Linton KJ. Evidence for a Sav1866- like architecture for the human multidrug transporter Pglycoprotein. FASEB J 2007; 21: 3937-48.
43. O'Mara ML, Tieleman DP. P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK. FEBS Lett 2007; 581: 4217-22.
44. Huang SY, Bolser D, Liu HY, Hwang TC, Zou X. Molecular modeling of the heterodimer of human CFTR's nucleotide-binding domains using a protein-protein docking approach. J Mol Graph Model 2009; 27: 822-8.
45. Kortagere S, Ekins S. Troubleshooting computational methods in drug discovery. J Pharmacol Toxicol Methods; 61: 67-75.
46. Wang C, Protasevich I, Yang Z, et al. Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis. Protein Sci; 19: 1932-47.
47. Protasevich I, Yang Z, Wang C, et al. Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci; 19: 1917-31.
48. Cui L, Aleksandrov L, Chang XB, et al. Domain interdependence in the biosynthetic assembly of CFTR. J Mol Biol 2007; 365: 981-94.
49. Lewis HA, Buchanan SG, Burley SK, et al. Structure of nucleotidebinding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J 2004; 23: 282-93.
50. Moran O, Galietta LJ, Zegarra-Moran O. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 2005; 62: 446-60.
51. Sampson HM, Robert R, Liao J, et al. Identification of a NBD1- binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol; 18: 231-42.
52. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4- phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997; 100: 2457-65.
53. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003; 278: 35079-85.
54. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67: 1797-807.
55. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991; 253: 202-5.
56. Jayaraman S, Haggie P, Wachter RM, Remington SJ, Verkman AS. Mechanism and cellular applications of a green fluorescent proteinbased halide sensor. J Biol Chem 2000; 275: 6047-50.
57. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for highthroughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 2001; 281: C1734-42.
58. Ma T, Thiagarajah JR, Yang H, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxininduced intestinal fluid secretion. J Clin Invest 2002; 110: 1651-8.
59. Trzcinska-Daneluti AM, Ly D, Huynh L, et al. High-content functional screen to identify proteins that correct F508del-CFTR function. Mol Cell Proteomics 2009; 8: 780-90.
60. Munkonge F, Alton EW, Andersson C, et al. Measurement of halide efflux from cultured and primary airway epithelial cells using fluorescence indicators. J Cyst Fibros 2004; 3 Suppl 2: 171-6.
61. Mansoura MK, Biwersi J, Ashlock MA, Verkman AS. Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery. Hum Gene Ther 1999; 10: 861-75.
62. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-9.
63. Gonzalez JE, Oades K, Leychkis Y, Harootunian A, Negulescu PA. Cell-based assays and instrumentation for screening ion-channel targets. Drug Discov Today 1999; 4: 431-439.
64. Loo TW, Bartlett MC, Clarke DM. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm 2005; 2: 407-13.
65. Wang Y, Loo TW, Bartlett MC, Clarke DM. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J Biol Chem 2007; 282: 33247-51.
66. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, Bear CE. A chemical corrector modifies the channel function of F508del- CFTR. Mol Pharmacol; 78: 411-8.
67. Robert R, Carlile GW, Liao J, et al. Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol; 77: 922-30.
68. Pedemonte N, Zegarra-Moran O, Galietta LJ. High-Throughput Screening of Libraries of Compounds to Identify CFTR Modulators. Methods Mol Biol; 741: 13-21.
69. Zegarra-Moran O, Romio L, Folli C, et al. Correction of G551DCFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol 2002; 137: 504-12.
70. Pedemonte N, Tomati V, Sondo E, Galietta LJ. Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol; 298: C866-74.
71. Neuberger T, Burton B, Clark H, Van Goor F. Use of Primary Cultures of Human Bronchial Epithelial Cells Isolated from Cystic Fibrosis Patients for the Pre-clinical Testing of CFTR Modulators. Methods Mol Biol; 741: 39-54.
72. Rowe SM, Pyle LC, Jurkevante A, et al. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther; 23: 268-78.
73. Moran O, Zegarra-Moran O. A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein. FEBS Lett 2005; 579: 3979-83.
74. Pasyk S, Li C, Ramjeesingh M, Bear CE. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosiscausing mutation associated with severe disease. Biochem J 2009; 418: 185-90.
75. Yu W, Kim Chiaw P, Bear CE. Probing conformational rescue induced by a chemical corrector of F508del-CFTR. J Biol Chem.
76. Wang X, Venable J, LaPointe P, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006; 127: 803-15.
77. Masters SL, O'Neill LA. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol Med; 17: 276-82.
78. Li C, Naren AP. Analysis of CFTR Interactome in the Macromolecular Complexes. Methods Mol Biol; 741: 255-70.
79. Scott-Ward TS, Cai Z, Dawson ES, et al. Chimeric constructs endow the human CFTR Cl-channel with the gating behavior of murine CFTR. Proc Natl Acad Sci USA 2007; 104: 16365-70.
80. Lubamba B, Lebacq J, Lebecque P, et al. Airway delivery of lowdose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009; 179: 1022-8.
81. Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999; 79: S193-214.
82. Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008; 321: 1837-41.
83. Sun X, Sui H, Fisher JT, et al. Disease phenotype of a ferret CFTRknockout model of cystic fibrosis. J Clin Invest; 120: 3149-60.
84. Ostedgaard LS, Meyerholz DK, Chen JH, et al. The DeltaF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs. Sci Transl Med; 3: 74ra24.
85. Ostedgaard LS, Rogers CS, Dong Q, et al. Processing and function of CFTR-DeltaF508 are species-dependent. Proc Natl Acad Sci USA 2007; 104: 15370-5.
86. Taylor C, Commander CW, Collaco JM, et al. A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies. Pediatr Pulmonol.
87. Wright FA, Strug LJ, Doshi VK, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet; 43: 539-46.